LV10054B - Antiviral or antibacterial compound and method of use - Google Patents

Antiviral or antibacterial compound and method of use Download PDF

Info

Publication number
LV10054B
LV10054B LVP-92-508A LV920508A LV10054B LV 10054 B LV10054 B LV 10054B LV 920508 A LV920508 A LV 920508A LV 10054 B LV10054 B LV 10054B
Authority
LV
Latvia
Prior art keywords
dimer
lysozyme
vas
ribonuclease
treatment
Prior art date
Application number
LVP-92-508A
Other languages
English (en)
Latvian (lv)
Other versions
LV10054A (lv
Inventor
Witold Kiczka
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of LV10054A publication Critical patent/LV10054A/xx
Publication of LV10054B publication Critical patent/LV10054B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
LVP-92-508A 1988-05-26 1992-12-28 Antiviral or antibacterial compound and method of use LV10054B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17858888A 1988-05-26 1988-05-26
PCT/US1988/001785 WO1989011294A1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound and method of use
OA59731A OA09785A (en) 1988-05-26 1990-01-26 Antiviral or antibacterial compound and method of use

Publications (2)

Publication Number Publication Date
LV10054A LV10054A (lv) 1994-05-10
LV10054B true LV10054B (en) 1995-02-20

Family

ID=33162813

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-508A LV10054B (en) 1988-05-26 1992-12-28 Antiviral or antibacterial compound and method of use

Country Status (23)

Country Link
US (3) US5200182A (da)
EP (1) EP0380484B1 (da)
JP (1) JPH0649659B2 (da)
AT (1) ATE93143T1 (da)
AU (1) AU624331B2 (da)
BG (1) BG60544B1 (da)
CA (1) CA1335425C (da)
CS (1) CS277030B6 (da)
DK (1) DK173078B1 (da)
ES (1) ES2011577A6 (da)
FI (1) FI900412A0 (da)
HK (1) HK42394A (da)
HU (1) HU204710B (da)
IL (1) IL90092A (da)
LV (1) LV10054B (da)
MA (1) MA21560A1 (da)
MW (1) MW390A1 (da)
OA (1) OA09785A (da)
PH (1) PH26284A (da)
RU (1) RU2092183C1 (da)
WO (1) WO1989011294A1 (da)
YU (1) YU109289A (da)
ZA (1) ZA893382B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2092183C1 (ru) * 1988-05-26 1997-10-10 Ника Хелт Продактс Лимитед (Лихтенштейн) Антивирусный или антибактериальный состав и способ его употребления
US5989880A (en) * 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers
WO1991010730A1 (en) * 1990-01-08 1991-07-25 Nika Health Products Ltd. Method of preparing ribonuclease dimers
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
CH682541A5 (de) * 1992-06-23 1993-10-15 Urs Viktor Dr Wirth Biochemische Inaktivierung von RNA-Viren.
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
JP2002187853A (ja) * 2000-12-21 2002-07-05 Shinei Ferumentekku:Kk 動物の乳頭除菌剤および菌環境改善方法
DE10210285A1 (de) * 2002-03-08 2003-11-13 Medigene Ag Reversibles Toxin und seine Verwendung
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US7348301B2 (en) * 2006-02-16 2008-03-25 Buckman Laboratories International, Inc. Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2134354A4 (en) * 2007-03-02 2012-03-21 Saint Simeon Lda COMPOSITION AND METHOD FOR THE TREATMENT OF PAPILLOMA VIRUS AND HORSE SARCODES
WO2009036000A2 (en) * 2007-09-11 2009-03-19 University Of Maryland, Baltimore Methods of treating a microbial infection by modulating rnase-l expression and/or activity
CA2702043A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
WO2010039985A1 (en) 2008-10-01 2010-04-08 Quintessence Biosciences, Inc. Therapeutic Ribonucleases
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
PL2457576T3 (pl) 2010-11-29 2021-04-06 Eurochit Danuta Kruszewska Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji
RU2548803C2 (ru) * 2011-11-28 2015-04-20 Общество с ограниченной ответственностью " Фарматренд" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ ИНФЕКЦИЙ P. Aeruginosa, СОДЕРЖАЩАЯ РЕКОМБИНАНТНЫЙ ЛИЗОЦИМ
RU2509801C2 (ru) * 2012-03-22 2014-03-20 Борис Михайлович Куриненко СПОСОБ ИСПОЛЬЗОВАНИЯ РИБОНУКЛЕАЗЫ Bacillus intermedius
EP2674162A1 (en) 2012-05-29 2013-12-18 Danuta Kruszewska Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
JP2015520773A (ja) 2012-05-29 2015-07-23 ダヌタ・クルセフスカDanutaKRUSZEWSKA ヒトおよび動物における予防および医薬に有用であるラクトバチルス・ロイテリdan80を含むナノ製品ならびにこれらの医薬用途
RU2504397C1 (ru) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
WO2014152678A1 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
JP5806434B1 (ja) 2014-02-21 2015-11-10 国立大学法人東京海洋大学 ノロウィルス不活化剤及びその製造方法、ノロウィルス不活化方法、ノロウィルス不活化用リゾチーム類の製造方法、ノロウィルス感染の予防薬又は治療薬、並びにノロウィルス不活化用皮膚外用剤
KR20170038829A (ko) * 2014-07-31 2017-04-07 큐피가부시키가이샤 함수 유동상 조성물 및 그 제조 방법, 그리고 리소자임 가공품 및/또는 그 염 그리고 그 제조 방법
BR122023020910A2 (pt) 2014-09-17 2024-01-30 Spogen Biotech Inc Método para fornecimento de proteínas ou peptídeos a um animal
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
RU2634264C1 (ru) * 2016-09-19 2017-10-24 Александр Ливиевич Ураков Крем-молочко для лечения опоясывающего лишая
CN113861760B (zh) 2016-12-28 2023-05-05 Dic株式会社 分散体
WO2021021765A1 (en) * 2019-07-26 2021-02-04 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1268M (fr) * 1961-06-29 1962-04-24 Puiseux Médicament antimitotique et antiviral.
FR4020M (da) * 1965-01-29 1966-03-21
DE1517751C3 (de) * 1965-07-08 1975-02-27 Eisai Co., Ltd., Tokio Verfahren zum Verhindern der Bildung von flockigen Lysozym- und/oder Lysozymsalzniederschlägen in wässrigen Lösungen, die Lysozym und/oder Lysozymsalze enthalten
DE1545644A1 (de) * 1965-12-06 1969-08-07 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen quaternaeren Scopolammoniumsalzen
GB1110504A (en) * 1966-03-18 1968-04-18 Prodotti Antibiotici Spa Pharmaceutical compositions
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
EP0187705A3 (en) * 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
RU2092183C1 (ru) * 1988-05-26 1997-10-10 Ника Хелт Продактс Лимитед (Лихтенштейн) Антивирусный или антибактериальный состав и способ его употребления

Also Published As

Publication number Publication date
AU1940888A (en) 1989-12-12
BG60544B1 (en) 1995-08-28
CS277030B6 (en) 1992-11-18
JPH03504121A (ja) 1991-09-12
DK16890D0 (da) 1990-01-22
US6099835A (en) 2000-08-08
HK42394A (en) 1994-05-13
CS318089A3 (en) 1992-05-13
PH26284A (en) 1992-04-10
FI900412A0 (fi) 1990-01-25
IL90092A (en) 1995-03-30
EP0380484A1 (en) 1990-08-08
DK173078B1 (da) 1999-12-20
OA09785A (en) 1994-04-15
ATE93143T1 (de) 1993-09-15
WO1989011294A1 (en) 1989-11-30
RU2092183C1 (ru) 1997-10-10
HUT54060A (en) 1991-01-28
US5466449A (en) 1995-11-14
LV10054A (lv) 1994-05-10
ZA893382B (en) 1991-01-30
MA21560A1 (fr) 1989-12-31
MW390A1 (en) 1990-11-14
ES2011577A6 (es) 1990-01-16
YU109289A (en) 1991-08-31
HU883981D0 (en) 1990-12-28
JPH0649659B2 (ja) 1994-06-29
EP0380484B1 (en) 1993-08-18
HU204710B (en) 1992-02-28
DK16890A (da) 1990-01-22
US5200182A (en) 1993-04-06
BG91270A (bg) 1993-12-24
AU624331B2 (en) 1992-06-11
CA1335425C (en) 1995-05-02

Similar Documents

Publication Publication Date Title
US6099835A (en) Method of using antiviral composition
EP0090837A1 (en) Method and composition for treating a patient suffering from interferonsusceptible disorder
CN109985069B (zh) 益生菌组合物及其用途
Al-Nakib et al. Intranasal chalcone, Ro 09–0410, as prophylaxis against rhinovirus infection in human volunteers
US6132715A (en) Method of inhibiting biosynthesis of tumor necrosis factor
US5342612A (en) Compositions for the treatment of mammalian diseases
Grimble et al. Non-specific urethritis and the tetracyclines.
KR930004599B1 (ko) 항바이러스성 또는 항균성 조성물
Ochs Treatment of external otitis; a simple and effective technic
Cox Cefazolin therapy of urinary tract infections
DE3883392T2 (de) Verwendung eines Lysozymdimeren und/oder Ribonucleasedimeren zur Herstellung eines antiviralen oder antibakteriellen Arzneimittels.
RO110037B1 (ro) Compoziții antivirale sau antibacteriene și metodă de tratare a infecțiilor, cu acestea
JOHNSON Dermatologic evaluation of yeast, tyrothricin, chlorophyll and nitrofurazone
Powell, SJ & MacLeod Ambilhar, a nitrothiazole derivative, in urinary tract bilharzia
Feo et al. Evaluation of tritheon (aminitrozole) in male trichomoniasis
MXPA97001730A (es) Vacuna enteral para infecciones vaginales